Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Huadong Medicine Co., Ltd. (stock code: 000963) was founded in 1993, headquartered in Hangzhou, Zhejiang, and listed on the Shenzhen Stock Exchange in December 1999. After more than 30 years of development, the company's business covers the entire pharmaceutical industry chain, with four major business segments: pharmaceutical industry, pharmaceutical distribution, medical aesthetics, and industrial microbiology. It has grown into a large comprehensive pharmaceutical listed company integrating innovative drug R&D, production, and distribution. The pharmaceutical industry segment focuses on the R&D, production, and sales of drugs for specialized treatments, chronic diseases, and special medications, with a complete manufacturing system oriented to international standards, forming core product lines in chronic kidney disease, immunology, oncology, endocrinology, digestive system, and cardiovascular diseases, among others. It holds multiple first-line clinical drugs with market advantages in China, and several products have obtained international registration certifications. Through independent development, external introduction, and project cooperation, the company strategically focuses its innovative drug R&D on three core therapeutic areas: endocrinology, autoimmune diseases, and oncology, building a differentiated innovative drug pipeline covering the entire R&D cycle and a well-structured product portfolio. The pharmaceutical distribution segment focuses on three core sectors: pharmaceuticals, medical devices, and herbal decoction pieces. Anchored by an intelligent logistics network, it strengthens competitiveness through specialized logistics for cold chain, special drugs, and vaccines, and its business scale consistently ranks first in Zhejiang Province. The pharmaceutical sector boasts comprehensive advantages including full product coverage, full-channel connectivity, efficient coordination between hospital and non-hospital channels, and deep synergy between distribution and agency. The medical device sector relies on a large-scale distribution network to support professional agency services, focusing on innovative businesses. The herbal decoction pieces sector has advantages across the entire industry chain, continuing to expand its provincial business through upgrades, efficiency improvements, and capacity expansion. Driven by digitalization and innovative services as core engines, the company builds a "comprehensive pharmaceutical service" ecosystem by integrating CSO cooperation, SPD supply chain management, and industry-academia-research projects, precisely linking upstream and downstream needs. Meanwhile, it focuses on three strategic pillars: organizational efficiency, cost control, and regional deepening, to continuously consolidate its industry position. The medical aesthetics segment aims to become a "top global medical aesthetics enterprise," adhering to the strategy of "globalized operations and dual-cycle business development." With international vision and forward-looking planning, it creates a comprehensive and differentiated product matrix, with product quantity and application areas ranking among the industry's forefront. It integrates "non-invasive + minimally invasive" technologies, "facial + body" areas, and "injection + energy-based devices" dimensions, achieving full coverage of regenerative products, hyaluronic acid, and botulinum toxin in injectables, forming a differentiated pipeline. It provides more professional, safe, efficient, and comprehensive solutions for beauty seekers, committed to becoming a top global provider of comprehensive medical aesthetic solutions. The industrial microbiology segment focuses on two strategic directions: synthetic biology technology innovation and biopharmaceutical industry upgrading, prioritizing four core business sectors: xRNA raw materials, specialty APIs & intermediates, health & biomaterials, and animal health.